MOLECULAR PARTNERS AG
MOLN · XNASCIK 1745114fmd_102YJ8A1XVNY2AV4S5TQR7WMM9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 12 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 20 | 9 | 10 | 190 | 7 | 5 | 0 |
| Research and development | 43 | 56 | 56 | 51 | 49 | 49 | 40 |
| Selling, general and administrative | 14 | 12 | 17 | 22 | 19 | 18 | 15 |
| Operating income | (37) | (58) | (63) | 117 | (61) | (61) | (58) |
| Interest expense | 1 | 5 | 1 | 1 | 5 | 0 | 5 |
| Income before taxes | (36) | (63) | (64) | 118 | (62) | (54) | (62) |
| Income tax expense | 0 | (0) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (36) | (63) | (64) | 118 | (62) | (54) | (62) |
| Net income | (36) | (63) | (64) | 118 | (62) | (54) | (62) |